Trials in humans have demonstrated that individuals with obesity exhibit elevated fasting amylin levels [191, 194–196] and greater postprandial amylin responses compared to lean individuals [194, 196, 197], even when obesity co-exists with T2DM on oral hypoglycemic agents [189]. The gene discussed is IAPP; the disease is obesity disorder.